Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

patients with histologically confirmed unresectable advanced or metastatic pancreatic cancer;
both sexes, age ≥18 years old;
ECOG performance status score ≤2;
the expected survival time was ≥3 months.

a known diagnosis of pancreatic cancer other than ductal adenocarcinoma;
treated with any systemic antitumor treatment before first-line chemotherapy onset;
died or lost to follow-up within one month after the initiation of first-line chemotherpay;
combined with other primary malignances.

The Value of Molecular Residual Disease Monitoring Based on ctDNA in Advanced or Metastatic Pancreatic Cancer